Evidence map›Paper›PMID 33643301›Full record

ArticleFrontiers in immunology2020

Domain-Scan: Combinatorial Sero-Diagnosis of Infectious Diseases Using Machine Learning.

Smadar Hada-Neeman, Yael Weiss-Ottolenghi, Naama Wagner, Oren Avram, Haim Ashkenazy, Yaakov Maor, Ella H Sklan, Dmitry Shcherbakov, Tal Pupko, Jonathan M Gershoni

Open access · goldAbstract readValidation Study
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Smadar Hada-NeemanThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Yael Weiss-OttolenghiThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Naama WagnerThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Oren AvramThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Haim AshkenazyMax Planck Institute for Developmental Biology, Max Planck Society (MPG), Tübingen, Germany.
Yaakov MaorInstitute of Gastroenterology and Hepatology, Kaplan Medical Center, Rehovot, Israel.
Ella H SklanDepartment of Clinical Microbiology and Immunology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Dmitry ShcherbakovRussian-American Anti-Cancer Center, Altai State University, Barnaul, Russia.
Tal PupkoThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Jonathan M GershoniThe Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
Tel Aviv University · ILAltai State University · RUKaplan Medical Center · ILMax Planck Institute for Developmental Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of pathogen-specific antibodies in an individual's blood-sample is used as an indication of previous exposure and infection to that specific pathogen (e.g., virus or bacterium). Measurement of the diagnostic antibodies is routinely achieved using solid phase immuno-assays such as ELISA tests and western blots. Here, we describe a sero-diagnostic approach based on phage-display of epitope arrays we term "Domain-Scan". We harness Next-generation sequencing (NGS) to measure the serum binding to dozens of epitopes derived from HIV-1 and HCV simultaneously. The distinction of healthy individuals from those infected with either HIV-1 or HCV, is modeled as a machine-learning classification problem, in which each determinant ("domain") is considered as a feature, and its NGS read-out provides values that correspond to the level of determinant-specific antibodies in the sample. We show that following training of a machine-learning model on labeled examples, we can very accurately classify unlabeled samples and pinpoint the domains that contribute most to the classification. Our experimental/computational Domain-Scan approach is general and can be adapted to other pathogens as long as sufficient training samples are provided.

Indexed as

Machine LearningPeptide LibraryAIDS SerodiagnosisAmino Acid SequenceAntigen-Antibody ReactionsBase SequenceCommunicable DiseasesDNA Barcoding, TaxonomicDNA, RecombinantEpitopesGenetic VectorsHepatitis CHepatitis C AntibodiesHepatitis C AntigensHigh-Throughput Nucleotide SequencingHIV AntibodiesDNA, RecombinantEpitopesgp160 protein, Human immunodeficiency virus 1Hepatitis C AntibodiesHepatitis C AntigensHIV AntibodiesHIV Core Protein p24HIV Envelope Protein gp160Oligonucleotidesp24 protein, Human Immunodeficiency Virus Type 1Peptide FragmentsPeptide LibraryDNA barcodesmachine learningnext-generation sequencingphage-displaysero-diagnostics

Identifiers

PMID33643301
PMCPMC7902724
OpenAlexW3128443087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.